AT1 blockers are effective in reducing brain inflammation after systemic inflammation caused by lipopolysaccharide, cerebrovascular inflammation caused by hypertension, cerebral ischemia and brain inflammatory response after traumatic brain injury (Benicky et al., 2011; Sironi et al., 2004; Timaru‐Kast et al., 2012; Zhou et al., 2005). The gene discussed is AGTR1; the disease is brain ischemia.